BIVI

BioVie Inc.

0.47 USD
+0.01 (+1.17%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

BioVie Inc. stock is down -5% since 30 days ago. The next earnings date is Aug 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 72.73% of the previous 10 June’s closed higher than May.

About BioVie Inc.

BioVie Inc. engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trials for Alzheimer's, Parkinson's and multiple myeloma and prostate cancer.